Highest-materiality recent filing
Board authorized TD Cowen to sell shares to affiliates under existing ATM with up to $60M aggregate offering.
Pulse Biosciences Q1 net loss $18.6M; accelerates NANOPULSE-AF enrollment to early Q4 2026
Preliminary Q1 2026: cash $68.3M, net loss $18.6M, cash used in ops $14.6M.
Pulse Biosciences reports 100% 6-month and 96% 12-month ablation success in nPulse study
Sustained 100% procedural success at 6 months (95/95 evaluable patients by holter).
Pulse Biosciences posts investor deck with nsPFA cath lab study details and 2026 goals
New details disclosed on pivotal clinical study of nsPFA Cardiac Catheter for atrial fibrillation.
Pulse Biosciences appoints Liane Teplitsky COO; expands Dr. Kenigsberg as full-time CMO
Liane Teplitsky named COO effective April 8, 2026; oversees Clinical, Regulatory, Quality, Commercial functions.
Pulse Biosciences enrolls first 7 patients in NANOPULSE-AF pivotal trial for nPulse AFib catheter
First 7 patients treated at St. Bernards Medical Center by Devi Nair, MD.
Pulse Biosciences awards CTO Darrin Uecker 100,000 RSUs for AFib product development
Restricted stock units cover 100,000 shares of common stock, par value $0.001.
Pulse Biosciences realigns to accelerate AFib catheter program after strong clinical data
100% acute success at 6 months (75/75 patients); 96% durable PVI at 12 months (45/47).
First-in-human cases completed at Sarasota Memorial and MD Anderson for T1N0M0 papillary thyroid microcarcinoma.
Pulse Biosciences reports 74% avg volume reduction in benign thyroid nodule ablation at 15-22 months
21 patients monitored 15-22 months; average 74% volume reduction of benign thyroid nodules with no regrowth.
Updated investor presentation posted on website includes summary financial info and product development update.
Pulse Biosciences CCO Kevin P. Danahy resigns effective immediately
Kevin P. Danahy, Chief Commercial Officer, resigned effective February 27, 2026.
Pulse Biosciences CCO Kevin Danahy resigns effective immediately
Kevin P. Danahy resigned as Chief Commercial Officer on February 27, 2026.
Pulse Biosciences enters $60M ATM equity distribution agreement with TD Cowen; terminates prior ATM
Entered equity distribution agreement with TD Cowen to sell up to $59,976,196 of common stock via ATM offerings.
Pulse Biosciences Q4 rev $264K, GAAP net loss $17.4M; FDA clears pivotal AF study
Q4 2025 revenue $264K (vs $86K Q3), full-year revenue $350K. GAAP net loss Q4 $17.4M, full year $72.8M (vs $53.6M prior year).
Pulse Biosciences reports 96% procedural success at 12 months for nPulse AF ablation study
100% procedural success at 6 months (75/75); 96% at 12 months (45/47) in first-in-human feasibility study.
Pulse Biosciences posts investor deck detailing progress on nPulse devices
Updated investor presentation highlights recent progress on nPulse Vybrance Percutaneous Electrode, Cardiac Clamp, and Cardiac Catheter.
Pulse Biosciences appoints Maria Sainz to Board of Directors and Audit Committee
Maria Sainz elected to Pulse Biosciences Board and Audit Committee effective January 8, 2026.
FDA approved IDE for Pulse Biosciences' nPulse Cardiac Catheter System to treat paroxysmal atrial fibrillation in NANOPULSE-AF study.
Six director nominees (Duggan, LaViolette, Soni, Uecker, van den Broek, Zanganeh) elected with 51.8M-53.1M votes each.
Pulse Biosciences initiates thyroid cancer study with MD Anderson; IDE approved
FDA-approved IDE for first-in-human feasibility study of nPulse Vybrance system in papillary thyroid microcarcinoma.
Pulse Biosciences posts updated investor presentation on nPulse product progress
Updated deck highlights recent progress on nPulse Vybrance Percutaneous Electrode, Cardiac Clamp, and Cardiac Catheter.
Pulse Biosciences Q3 2025 revenue $86k, GAAP net loss ($19.4M), cash $95.2M
Revenue of $86k from limited market release of nPulse Vybrance system.
Pulse Biosciences enrolls first patient in NANOCLAMP AF study for AF treatment using nPulse system
First procedure completed at St. Helena Hospital in St. Helena, CA with nPulse Cardiac Surgical System using nanosecond PFA.
Pulse Biosciences reports 94% PVI success at 3 months in nPulse cardiac study
All (100%) posterior box isolations acutely successful in high-dose cohort; 94% PVI success per vein at ~3 months.
Pulse Biosciences stockholders approve equity plan amendment and ratify director options
Stockholders approved increasing Equity Plan shares by 2 million and changing Consultant definition.
Pulse Biosciences receives FDA IDE approval for nsPFA Cardiac Surgery Study NANOCLAMP AF
FDA granted IDE approval for the NANOCLAMP AF study of nsPFA Cardiac Surgical System to treat atrial fibrillation.
Pulse Biosciences enrolls first patients in PRECISE-BTN study for benign thyroid nodules
First successful procedures using nsPFA Percutaneous Electrode System for benign thyroid nodules (BTNs).
Pulse Biosciences publishes FIH data for nsPFA thyroid nodule treatment in Thyroid journal
Single-arm feasibility study by Prof. Spiezia at Ospedale del Mare, Naples, Italy; three cohorts.
GAAP net loss ($19.2M) vs ($11.4M) YoY; non-GAAP net loss ($13.7M) vs ($9.0M).
Pulse Biosciences names Steven T. Weber as VP Accounting and principal accounting officer
Steven T. Weber appointed VP of Accounting and Global Corporate Controller effective July 14, 2025, succeeding as principal accounting officer.
Pulse Biosciences Q1 net loss widens to $16.8M; cash $119.3M; clinical milestones set
GAAP net loss of $16.8M vs $10.1M in Q1 2024; non-GAAP net loss $11.4M vs $8.1M.
Pulse Biosciences Q4 GAAP net loss widens to $19.4M; cash boosted to $118M on warrant exercises
GAAP net loss of $19.4M in Q4 2024 vs $11.9M a year ago; full-year loss $53.6M vs $42.2M.
Pulse Biosciences appoints Jon Skinner as CFO effective Feb 3, 2025
Jon Skinner appointed CFO effective Feb 3, 2025; previously VP at Copeland and Imperative Care.
Pulse Biosciences reports 92.4% PVI success at ~3 months in nsPFA catheter feasibility study
77 patients treated; first 30 evaluated at ~3 months remap with 92.4% PVI success (109/118 veins).
Pulse Biosciences posts updated investor deck highlighting CellFX nsPFA device progress
Updated deck discloses progress on CellFX nsPFA 360 Cardiac Catheter development.
Paul LaViolette, former Co-Chairman, becomes CEO and President effective Jan 9, 2025.
Pulse Biosciences redeems 150% warrants; $16.50 VWAP trigger met over 20 days
VWAP exceeded $16.50 for 20 consecutive trading days; average VWAP of $18.85 during period.
Pulse Biosciences CEO Barrett resigns; Danahy, Uecker named interim executives
CEO Burke T. Barrett resigns effective Dec 6, 2024; also leaves board Dec 2, 2024.
Controlling stockholder Robert Duggan cleared to buy up to 500k PLSE shares by Dec 10
Robert W. Duggan, controlling stockholder and Co-Chairman, authorized to purchase up to 500,000 shares of common stock through December 10, 2024.
Pulse Biosciences: nano-PFA reduces benign thyroid nodule volume >50% in feasibility study
First-in-human study (30 patients) shows ≥50% nodule volume reduction and symptomatic relief within 1 month.
Pulse Biosciences Q3 net loss $12.7M; appoints Dr. Kenigsberg as CMO for Electrophysiology
GAAP net loss $12.7M in Q3 2024 vs $10.6M in Q3 2023; cash $79M including $60M rights offering.
Pulse Biosciences reports Q2 prelim costs $11.7M; appoints Paul LaViolette as Co-Chairman
GAAP costs and expenses $11.7M for Q2 2024; non-GAAP $9.4M; cash $26.2M as of June 30, excluding $60M rights offering closed July 2024.
Pulse Biosciences posts updated investor presentation on website; no new financial data disclosed
Updated deck highlights progress on CellFX nsPFA 360 Cardiac Catheter, Cardiac Surgery System, and Percutaneous Electrode.
Successfully treated first two AFib patients using nano-PFA Cardiac Surgery System at St. Antonius Hospital, Netherlands.
Pulse Biosciences enters $60M ATM equity facility; prelim Q2 net loss $10.7-12.7M
Up to $60M at-the-market offering via Canaccord Genuity and Needham; commission up to 3%.
FDA Breakthrough Device Designation for CellFX nsPFA Cardiac Surgery System to treat atrial fibrillation.
Pulse Biosciences closes $60M rights offering at $10/unit, oversubscribed 138%
Raised $60M gross from 6M units; each unit = 1 share + 2 warrants to buy 0.5 share at $11.
Pulse Biosciences rights offering oversubscribed, raises $60M; Duggan to hold ~72%
Offering oversubscribed at 138%, receiving over $83M in subscriptions vs $60M limit.
Pulse Biosciences 2024 annual meeting elects five directors; Spray not reelected
Director Shelley Spray did not stand for reelection at June 6, 2024 meeting; no disagreement with company.
Pulse Biosciences, Inc. (the “Company”) has appointed Jon Skinner as Chief Financial Officer of the Company, effective as of February 3, 2025
The Board of Directors of Pulse Biosciences, Inc. (the “Company”) has appointed Paul A. LaViolette, current Co-Chairman of the Board, as Chief Executive Officer and President of the Company, effective as of January 9, 2025
the Board appointed Robert W. Duggan and Mr. LaViolette to serve as Co-Chairmen of the Board
the Board of Directors of Pulse Biosciences, Inc. (the “Company”) elected Paul A. LaViolette to serve as a member of the Company’s Board of Directors
the Board appointed Robert W. Duggan and Mr. LaViolette to serve as Co-Chairmen of the Board
Director Shelley D. Spray did not stand for reelection at the Annual Meeting.
The Board of Directors of Pulse Biosciences, Inc. (the “Company”) has appointed Burke T. Barrett as President and Chief Executive Officer of the Company and as a director, in each case effective as of May 12, 2024
The Board of Directors of Pulse Biosciences, Inc. (the “Company”) has appointed Burke T. Barrett as President and Chief Executive Officer of the Company and as a director, in each case effective as of May 12, 2024
Mr. Barrett succeeds Kevin P. Danahy, who was appointed as the Company’s Chief Commercial Officer, as of the Start Date
Max materiality 0.80 · Median 0.60 · Most common event other_material